logo

FDA Calendar

Share
PDUFA dates and FDA Panel Review dates are very important because they are make or break events for biostocks when the decisions are announced. Also, usually biostocks experience a run-up going into the scheduled decision/review dates. So having prior knowledge of the catalysts goes a long way toward maximizing profit or minimizing loss while trading volatile biotech stocks.

Listed below are large cap, mid cap and small cap stocks with pending regulatory catalysts.

Get in-depth analysis and insight on investing in the high-stakes biotech and pharma sectors. Check out our
premium biotech research product and our biotech home page.
Company Name
Ticker
Drug
Event
Date
Outcome
Details
EyePoint Pharmaceuticals, Inc.
Durasert (NDA)
FDA decision on Durasert for posterior segment uveitis
11/05/2018
EyePoint Pharmaceuticals, Inc.
Durasert micro-insert (NDA)
FDA decision on Durasert micro-insert for non-infectious posterior segment uveitis
11/05/2018
Trevena, Inc.
OLINVO (NDA)
FDA panel to review OLINVO for management of moderate to severe acute pain
11/02/2018
Regeneron Pharmaceuticals
cemiplimab (BLA)
FDA decision on cemiplimab for metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC
10/28/2018
TherapeuticsMD
TX-001HR (NDA)
FDA decision on TX-001HR for vasomotor symptoms due to menopause
10/28/2018
Merck & Co Inc.
Doravirine (NDA)
FDA decision for use of Doravirine with lamivudine and tenofovir disoproxil fumarate for HIV
10/23/2018
Regeneron Pharmaceuticals
DUPIXENT (sBLA)
FDA decision on DUPIXENT for moderate-to-severe asthma
10/20/2018
Sanofi
DUPIXENT (sBLA)
FDA decision on DUPIXENT for moderate-to-severe asthma
10/20/2018
Akcea Therapeutics Inc.
Inotersen
FDA decision on Inotersen for hereditary TTR amyloidosis (hATTR)
10/06/2018
Verastem, Inc.
Duvelisib (NDA)
FDA decision on Duvelisib for relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
10/05/2018
Antares Pharma Inc.
XYOSTED injection(Resubmitted NDA)
FDA decision on XYOSTED injection for adult men with testosterone deficiency
09/29/2018
Insmed Inc
ALIS (Amikacin Liposome Inhalation Suspension) (NDA)
FDA decision on ALIS for adult patients with nontuberculous mycobacterial lung disease
09/28/2018
Merck & Co Inc.
KEYTRUDA (sBLA)
FDA decision on Keytruda in combination with ALIMTA and platinum chemotherapy (carboplatin or cisplatin) for metastatic nonsquamous non-small cell lung cancer
09/23/2018
Teva Pharmaceutical Industries Limited
Fremanezumab (BLA)
FDA decision on Fremanezumab for the treatment of migraine
09/16/2018
Roche Holding AG
TECENTRIQ (sBLA)
FDA decision on TECENTRIQ in combination with Avastin or bevacizumab, paclitaxel and carboplatin or chemotherapy for initial treatment of people with metastatic NSCLC
09/05/2018
pharma-daily-051718.jpg Today's Daily Dose brings you news about Anika's accelerated share repurchase program; Esperion's phase III study results of bempedoic acid in patients with hypercholesterolemia; TherapeuticsMD and Teva's near-term catalysts.
pharma-daily-052218.jpg Today's Daily Dose brings you news about FDA approval of AstraZeneca's hyperkalemia drug; Dova's platelet booster Doptelet getting regulatory nod; the fifth indication for Amgen's Prolia securing thumbs-up; Sesen's encouraging three-month data from the VISTA trial and investors' concern and Nabriva's LEAP 2 study results.
pharma-daily-051718.jpg Another week has gone by, and it was raining FDA approvals. Now, here are some of the pharma/biotech stocks and upcoming events to keep an ear out for in the coming week.
Read More
A study conducted on mice by researchers of the University of Montreal, led by Jean-François Côté, have found a link between a certain protein called AXL and metastases in HER2-positive breast cancer.
Read More